Clinical Trial Update: Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating epirubicin and cyclophosphamide followed by docetaxel and trastuzumab in HER2-positive breast cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED